These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 8353034)

  • 1. Surrogate endpoints.
    Ellenberg SS
    Br J Cancer; 1993 Sep; 68(3):457-9. PubMed ID: 8353034
    [No Abstract]   [Full Text] [Related]  

  • 2. The use of surrogate endpoints in clinical trials: focus on clinical trials in cardiovascular diseases.
    Lonn E
    Pharmacoepidemiol Drug Saf; 2001; 10(6):497-508. PubMed ID: 11828831
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endpoints in cancer clinical trials.
    Fiteni F; Westeel V; Pivot X; Borg C; Vernerey D; Bonnetain F
    J Visc Surg; 2014 Feb; 151(1):17-22. PubMed ID: 24440056
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can the long road from bench to bedside be shortened?
    Gottlieb N
    J Natl Cancer Inst; 2001 May; 93(10):738-40. PubMed ID: 11353779
    [No Abstract]   [Full Text] [Related]  

  • 5. Surrogate End Points and Their Validation in Oncology Clinical Trials.
    Zhao F
    J Clin Oncol; 2016 May; 34(13):1436-7. PubMed ID: 26951314
    [No Abstract]   [Full Text] [Related]  

  • 6. Potential surrogate endpoints in cancer research--some considerations and examples.
    Duffy SW; Treasure FP
    Pharm Stat; 2011; 10(1):34-9. PubMed ID: 20029937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarkers as surrogate endpoints in cancer trials.
    Dunn BK; Akpa E
    Semin Oncol Nurs; 2012 May; 28(2):99-108. PubMed ID: 22542317
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Statistical considerations for the next generation of clinical trials.
    Wu W; Shi Q; Sargent DJ
    Semin Oncol; 2011 Aug; 38(4):598-604. PubMed ID: 21810519
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biological markers: Tailoring treatment and trials to prognosis.
    Kerr DJ; Shi Y
    Nat Rev Clin Oncol; 2013 Aug; 10(8):429-30. PubMed ID: 23752731
    [No Abstract]   [Full Text] [Related]  

  • 10. Does the decision in a validation process of a surrogate endpoint change with level of significance of treatment effect? A proposal on validation of surrogate endpoints.
    Sertdemir Y; Burgut R
    Contemp Clin Trials; 2009 Jan; 30(1):8-12. PubMed ID: 18809512
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Surrogate endpoints for overall survival in lung cancer trials: a review.
    Fiteni F; Westeel V; Bonnetain F
    Expert Rev Anticancer Ther; 2017 May; 17(5):447-454. PubMed ID: 28399678
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An approach to the validation of markers for use in AIDS clinical trials.
    Mildvan D; Landay A; De Gruttola V; Machado SG; Kagan J
    Clin Infect Dis; 1997 May; 24(5):764-74. PubMed ID: 9142767
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction to special issue on biomarker-based clinical trial designs in oncology.
    Sargent DJ; Mandrekar S; Grothey A
    Chin Clin Oncol; 2015 Sep; 4(3):28. PubMed ID: 26408295
    [No Abstract]   [Full Text] [Related]  

  • 14. Surrogate endpoints.
    Fleming TR; DeGruttola V; DeMets DL
    AIDS Clin Rev; 1997-1998; ():129-43. PubMed ID: 9305447
    [No Abstract]   [Full Text] [Related]  

  • 15. Achieving the goals of effective, safe, and individualized cancer care.
    Roberts SA; Karnes EK; Allen JD; Benner JS; Sigal EV; McClellan M
    Clin Cancer Res; 2011 Nov; 17(21):6632-3. PubMed ID: 22046023
    [No Abstract]   [Full Text] [Related]  

  • 16. Use of meta-analysis for the validation of surrogate endpoints and biomarkers in cancer trials.
    Buyse M
    Cancer J; 2009; 15(5):421-5. PubMed ID: 19826362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Statistical evaluation of surrogate markers: validity, efficiency, and sensitivity.
    Qu Y
    Clin Trials; 2013 Oct; 10(5):693-5. PubMed ID: 23988465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Surrogate endpoints].
    Hill C
    Bull Cancer; 1999; 86(7-8):622-4. PubMed ID: 10477379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers as Surrogate Endpoints: Ongoing Opportunities for Validation.
    Zhang AD; Ross JS
    J Law Med Ethics; 2019 Sep; 47(3):393-395. PubMed ID: 31560627
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Surrogate and true endpoints in cancer clinical trials].
    Nakajima T; Ohta K; Ohyama S; Yamaguchi T
    Gan To Kagaku Ryoho; 2000 May; 27(5):671-5. PubMed ID: 10832433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.